TME Pharma N.V.
ALTME.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.00 | 0.00 |
| FCF Yield | -37.99% | -93.17% | -67.63% | -0.15% |
| EV / EBITDA | -3.92 | 0.45 | -0.51 | -0.16 |
| Quality | ||||
| ROIC | -148.15% | -151.74% | -162.31% | -325.90% |
| Gross Margin | 0.00% | -63.16% | 0.00% | 100.00% |
| Cash Conversion Ratio | 1.36 | 0.77 | 0.84 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -27.51% | -39.56% | -39.56% |
| Free Cash Flow Growth | -49.66% | 30.28% | -122,211.47% | 34.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.09 | 1.27 | 1.01 | 0.38 |
| Interest Coverage | -9.02 | 0.00 | -5.28 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 103.33 | -9,821.84 | -1,416.82 | 217.06 |